Lotus Eye Hospital and Institute growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+8.4%+2.8%+2.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−1.5%−47.4%−13.9%
−185.9%−84.8%−39.2%
−89.1%−74.6%−28.5%
−88.9%−74.3%−28.6%
+18.7%+4.4%+5.4%
+0.2%+1.0%+3.2%
−36.6%−13.0%+29.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹229 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+2.5+2.8+8.4—
EBITDA Growth—-13.9-47.4-1.5—
EBIT Growth—-39.2-84.8-185.9—
Net Income Growth—-28.5-74.6-89.1—
EPS Growth—-28.6-74.3-88.9—
Total Assets Growth—+5.4+4.4+18.7—
Total Equity Growth—+3.2+1.0+0.2—
Cash from Operations Growth—+29.5-13.0-36.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.